The results showed that although SGLT-2 inhibitors can help reduce the risk of CV death or HHF (27% overall, 25% for HF, 12% for T2DM) and HHF (28% overall, 33% for HF, 23% for T2DM), no significant differences were observed in CV death and all-cause mortality. Here, SLC5A2 is linked to type 2 diabetes mellitus.